Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 8,144 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

NCT03986944
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
107
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

NCT05127434
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
36,814 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
133
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

NCT00107198
View directory record Official record
Conditions
Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
Interventions
Conventional Surgery, Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone, Radiation Therapy, Vincristine Sulfate
Procedure · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Month to 21 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
147
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

NCT01319487
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Phoenix, Arizona • Fort Myers, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Intraoperative Warming Devices

NCT00711867
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
VH2, Bair Hugger
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain

NCT00108771
View directory record Official record
Conditions
Pain
Interventions
ZR-02-01 Fentanyl Transdermal Matrix Patch, Placebo Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • San Diego, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

NCT00446199
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes
Interventions
0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132
View directory record Official record
Conditions
Menopause, Osteoporosis
Interventions
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
143
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 17, 2026, 1:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT05019521
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Danicopan, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
49
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 17, 2026, 1:42 PM EDT
Completed No phase listed Observational

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

NCT06667414
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 60 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT02100514
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615; RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
108
States / cities
Alexander City, Alabama • Auburn, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

NCT01231906
View directory record Official record
Conditions
Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions
Cyclophosphamide, Dexrazoxane, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Vincristine Sulfate
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 149 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 3 Interventional

Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

NCT03617367
View directory record Official record
Conditions
Cervical Dystonia
Interventions
daxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 17, 2026, 1:42 PM EDT
Recruiting Phase 3 Interventional

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

NCT07546500
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Investigator's choice of Chemotherapy, Azenosertib
Drug
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
12
States / cities
Phoenix, Arizona • Antioch, California • Beverly Hills, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 1:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

NCT01078636
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

NCT00567164
View directory record Official record
Conditions
Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions
EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,887 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
85
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

NCT01498328
View directory record Official record
Conditions
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma
Interventions
Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 17, 2026, 1:42 PM EDT
Recruiting Not applicable Interventional

Early-Stage Partner in Care Living Alone Plus

NCT06962111
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment (MCI), Alzheimer Disease
Interventions
Psychoeducational skills training intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
60 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 3 Interventional

An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

NCT01483898
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Ixmyelocel-T, Placebo
Biological · Other
Lead sponsor
Vericel Corporation
Industry
Eligibility
35 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 17, 2026, 1:42 PM EDT
Completed No phase listed Observational

Insulin Secretory Defects in Pima Indians at High Risk for NIDDM

NCT00410800
View directory record Official record
Conditions
NIDDM
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Not applicable Interventional

Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases

NCT00007007
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Radiation Toxicity
Interventions
management of therapy complications, quality-of-life assessment
Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
223
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 174 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 17, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

NCT05600036
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ESK-001, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 17, 2026, 1:42 PM EDT
Recruiting Phase 3 Interventional

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

NCT06690398
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Lumateperone high dose, Lumateperone low dose, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
35
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 1:42 PM EDT